Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T12:50:32.434Z.
Calculation as of: 2026-10-06T12:50:32.434Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6e30e9273cc74abd864e2fca08a62f10ee0154e442432ff18a73c00261064cea
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$478.54M
EV/EBIT Ratio
N/A
TTM Avg
5.92x
3Y Avg
17.76x
5Y Avg
17.76x
Market Cap
$487.30M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$453.70M
EV/EBIT Ratio
N/A
TTM Avg
84.81x
3Y Avg
33.20x
5Y Avg
21.83x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arvinas, Inc. (ARVN) | $481.33M | N/A | N/A | N/A | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | N/A | 5.92x | 17.76x | 17.76x |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.30M | N/A | N/A | N/A | N/A |
| Cerus Corporation (CERS)vs › | $471.57M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | N/A | 64.08x | 60.43x | 132.37x |
| Evolus, Inc. (EOLS)vs › | $491.93M | N/A | N/A | N/A | N/A |
| NRC Health (NRC)vs › | $468.31M | 37.66x | 22.84x | 18.67x | 19.86x |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $453.70M | N/A | 84.81x | 33.20x | 21.83x |
| Assembly Biosciences, Inc. (ASMB)vs › | $450.64M | N/A | N/A | N/A | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $447.43M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
